Staffan Encrantz has bought SGHT on 10 days since Oct 2021

Staffan Encrantz is an individual corporate insider who serves as Chairperson of the Board and an independent director of Sight Sciences, Inc. (NASDAQ: SGHT), where he also sits on the Audit Committee and Commercial Strategy Committee.( He is a significant shareholder in the company, holding over 1.4 million shares directly following equity awards and open‑market purchases, and reporting additional indirect holdings through the 1997 Staffan and Margareta Encrantz Revocable Trust and Allegro Investment Fund, L.P., for which he serves as a control person while disclaiming beneficial ownership beyond any pecuniary interest.( In recent insider transactions, Encrantz has continued to increase his stake in Sight Sciences through open‑market stock purchases and director equity compensation, underscoring his long‑term alignment with shareholders.(

Outside of his board role at Sight Sciences, Encrantz is identified in SEC filings as the president, chairman/CEO, and sole director of Allegro Investment Inc., reflecting a broader background in investment management and corporate leadership.( Public filings emphasize his more than 30 years of business experience and long‑standing involvement with Sight Sciences, where he has served on the board and as its chairperson since the company’s growth from a private venture‑backed business into a publicly traded ophthalmic medical device company focused on innovative treatments for eye disease.( Specific details of his early career and formal education are not disclosed in the available public sources.(

Written by Perplexity from public sources.